At a glance
ClinicalIndex Comparison RecordN/ACompleted· 143 enrolled
Drug / intervention
Antioxidant Cocktail +2 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Estrogen-Mediated Impairments of Vascular Health in Diabetes
In Brief
A clinical study evaluating Antioxidant Cocktail, Resveratrol, and 1 other intervention for Diabetes Mellitus, Type 1. Completed, enrolled 143 participants across 2 sites.
Detailed Summary
Diabetes has recently been referred to as "the epidemic of the 21st century". The reason why women with type 1 diabetes have a 2-3 fold greater risk of cardiovascular disease (CVD) compared to men with type 1 diabetes is unknown.The purpose of this study is to investigate whether or not estrogen contributes to vascular dysfunction in premenopausal women with diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 1
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
First PostedFeb 2018
Enrollment StartApr 2018
Primary CompletionSep 2023
Study CompletionDec 2023
TodayJul 2026
First PostedFeb 19, 2018
Enrollment StartApr 17, 2018
Primary CompletionSep 1, 2023
Study CompletionDec 31, 2023
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 8.4 years ago
Interventions
Antioxidant Cocktaildietary
Vitamin C, Vitamin E, alpha lipoic acid
Resveratroldietary
1500 mg trans-resveratrol
Placeboother
placebo